KEAP1/NRF2 signalling regulates glutaminolysis metabolism by inhibition of glutaminase in KRAS-KEAP1 mutant lung cancer [53] and regulates the sensitivity to EGFR-TKI. Here, KRAS is linked to lung cancer.